The triptolide nanoparticle with a CRPPR peptide-modified micelle to target the tumor microenvironment, following the priming action of a-mangostin-loaded nanoparticles that target CAFs and disrupt TGF-β signaling, leading to robust tumor growth suppression through a sequential targeting approach [1028]. Here, TGFB1 is linked to neoplasm.